Femasys is trading 24.05% up now at $2.73, primarily as biotechnology shares rallied after positive Moderna and Merck Phase 3 melanoma-vaccine results.
- The personalized mRNA vaccine met key trial goals, lifting Moderna sharply and improving sentiment across biotech companies.
- No new Femasys-specific announcement was identified on August 19, 2026; the move appears primarily sector-driven rather than connected to the August 14 earnings update.
- Trading activity is elevated, though reliable volume data was unavailable.